2,4-Dimethoxybenzonitrile | CAS:4107-65-7

We serve 2,4-Dimethoxybenzonitrile CAS:4107-65-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4-Dimethoxybenzonitrile

Chemical Name:2,4-Dimethoxybenzonitrile
CAS.NO:4107-65-7
Synonyms:2,4-Dimethoxybenzonitrile
1-cyano-2,4-dimethoxybenzene
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 306.7±22.0 °C at 760 mmHg
Melting Point 93-94 °C(lit.)
Molecular Formula C9H9NO2
Molecular Weight 163.173
Flash Point 128.8±15.6 °C
Vapour Pressure 0.0±0.7 mmHg at 25°C
Index of Refraction 1.520
 
Specification:
Appearance:Light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2,4-Dimethoxybenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-cyano-2,4-dimethoxybenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Dimethoxybenzonitrile Use and application,2,4-Dimethoxybenzonitrile technical grade,usp/ep/jp grade.


Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate manufacturer Taiwan is denying entry to Chinese nationals from Guangdong, a southern coastal province that has also been battered by the virus, and travelers who have recently visited the area.1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(2-triphenylenyl)- supplier The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself.1-FLUORO-8-IODOOCTANE vendor The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.